搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
生物谷
2 天
后PD-1时代,免疫联合治疗的「得」与「失」
该系列试验,并没有使用TIGIT作为生物标志物,但Treg细胞中较高的TIGIT:CD226比率,与接受ICIs治疗的晚期黑色素瘤患者不良临床结果相关,这代表了一个可能值得进一步探索的生物标志物。 另一个TIGIT系列研究是KEYVIBE,主角是vibostolimab + 帕博利珠单抗复合制剂(MK ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Alabama mass shooting
San Francisco homelessness
CA firefighter held for arson
Donlon's homes searched
Ga. suspect's mom indicted
To skip Al Smith dinner
Actress Crosby dies at 90
Former WA governor dies
Rejects CNN debate invite
CAH sues for trespassing
ISR raids Al Jazeera office
Biden hosts 'Quad' summit
Iran coal mine blast
Suns broadcaster dies
CA bill to protect kids online
House repeals emission rules
J&J unit files for bankruptcy
Feds subpoena Schaeffer
Released after guilty plea
Pandas leaving for China
Beirut strike death toll
Drug price challenge revived
Boeing defense chief exits
Hand count approved in GA
FDA approves flu vaccine
WI high court to decide
SC 1st execution in 13 years
Sesame Place suit verdict
TN abortion law blocked
Bill to boost security OK'd
ISR strike on Gaza school
Hezbollah rockets hit Israel
反馈